Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Dr Reddy's secures deal with Gilead to produce COVID-19 drug; share price rises 3%

Company will receive technology transfer from Gilead for manufacturing of this drug.

June 15, 2020 / 11:02 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Dr Reddy's Laboratories share price rose 3 percent intraday on June 15 after the company entered a non-exclusive licensing agreement with Gilead Sciences.

The company has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc that will grant Dr Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for CCOVID-19, in 127 countries including India.

The company will receive technology transfer from Gilead for the manufacturing of this drug.

Dr Reddy’s would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries.

Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the US Food and Drug Administration (USFDA) to treat Covid-19.

At 10:47 hrs, Dr Reddy’s Laboratories was quoting at Rs 4,027.85, up Rs 21.20, or 0.53 percent on the BSE.

Moneycontrol News
first published: Jun 15, 2020 11:02 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347